Skip to main content

Advertisement

Table 3 Univariate subgroups analysis of progression-free survival

From: Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

  FOLFOX-4 TOPOTECAN  
No. patients No. events Median PFS (95% CI) No. patients No. events Median PFS (95% CI) P
Site of metastasis
 Only abdominal 11 10 2.8 (0.6–5.6) 20 20 2.7 (1.1–3.6) 0.617
 Abdominal+extra-abdominal 18 18 2.8 (1.7–7.0) 6 6 5.0 (0.9–10.7) 0.941
P    0.544    0.211  
Lines of previous treatments
  ≤ 4 15 15 2.6 (0.6–4.6) 20 20 3.2 (1.6–5.4) 0.948
  > 4 14 13 2.8 (1.7–8.4) 6 6 2.2 (0.7–4.9) 0.124
P    0.401    0.054  
Baseline NLR
  < 3 13 12 3.0 (2.4–18.5) 20 20 2.9 (1.6–5.1) 0.142
  ≥ 3 15 15 1.9 (0.7–4.6) 5 5 2.5 (1.0–6.6) 0.690
P    0.075    0.388  
Baseline PLR
  < 210 13 12 2.9 (0.7–18.5) 18 18 2.9 (1.6–5.1) 0.235
  ≥ 210 15 15 2.5 (0.9–4.6) 7 7 2.5 (0.9–3.5) 0.539
P    0.177    0.154  
  1. Abbreviation. FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil, CI confidence interval, NLR neutrophil-to-lymphocyte ratio, PFS progression-free survival, PLR platelet-to-lymphocyte ratio